CancerNeo®

• Whole exome sequencing of tumor/normal tissue using CeGaT’S ExomeXtra®
• Detailed assessment of somatic variants detected in more than 700 tumor-relevant genes and fusions in more than 30 genes
• Medical report with:
  • validated list of variants with potential therapeutic relevance
  • treatment options based on somatic variants
  • TMB determination/MSI prediction/ HRD score calculation
  • detection of copy number variants (CNVs)
  • a list of all eligible drugs, with EMA and/or FDA approval, for which corresponding biomarkers could be detected in the tumor
  • determination of pharmacogenetically relevant germline variants affecting the metabolism of certain tumor drugs or anesthetics
  • assessment of the evidence for CHIP (Clonal Hematopoiesis of Indeterminate Potential)
• Tumor whole RNA sequencing with rRNA depletion
• HLA typing
• Prediction of HLA class I restricted peptide epitopes (neoepitopes) spanning tumor-specific variants from sequencing data
• Selection of most relevant neoepitopes for HLA class I and HLA class II
• Second medical report with selected peptides for formulation of a vaccine

• RNA-based fusion transcript analysis (CancerFusionRx®) covering over 150 genes for fusion detection and over 120 exon-exon-specific enrichments with known breakpoints — learn more
• Immunohistochemical (IHC) analyses: PD-L1, CAR-T cell panel, HLA class I and class II staining (external) — learn more
• MGMT promoter methylation analysis

Neoepitopes can be recognized by CD8+ cytotoxic T cells (CTL) and by CD4+ T helper cells. Neoepitopes recognized by CD8+ T cells are typically 8-12 amino acids long and presented by HLA class I molecules, while neoepitopes recognized by CD4+ T helper cells are usually longer (13-18 amino acids in length) and presented by HLA class II molecules. For successful immunotherapy, neoantigen selection should include short and long peptides to activate both, CD4+ and CD8+ T cells. Immune responses of each individual patient can be monitored during anti-cancer vaccination by flow cytometry-based analysis of neoepitope-specific T cell activation.

Our cancer immunology experts use in silico algorithms based on exome sequencing and HLA typing to predict and select up to 12 eligible neoantigen epitopes individualized for each patient. The selected peptides are predicted to activate not only cytotoxic T cells but also T helper cells. Therefore, in addition to short peptides (8-12 amino acids) potentially binding to HLA class I molecules also long peptides (~17 amino acids) potentially binding to HLA class II molecules are included. To confirm the expression of the selected neoepitopes, transcriptome data by RNA sequencing of the tumor sample is done in parallel. In cases of no availability of RNA, information about neoepitope expression is retrieved from protein expression databases

To complete our genetic diagnostics, we offer to organize immunohistochemistry analysis on the tumor sample in cooperation with partner laboratories. We forward the pathological examination reports upon completion.

Detection of expression in the tumor tissue of the Programmed death-ligand 1 (PD-L1) is important for selecting patients which may benefit (the most) from immunotherapy, such as pembrolizumab.

Detection of MGMT promotor methylation in the tumor tissue is important for glioma patients since it is a potential biomarker of sensitivity to alkylating chemotherapy, including temozolomide (TMZ).

HLA molecules present tumor antigens to T cells. Expression analysis of HLA-molecules is a helpful tool to tailor your immune-therapeutic strategy.

The CAR T cell panel detects eight different target antigens of CAR-T Cell therapies in clinical or preclinical development.

Chromosomal rearrangements frequently occur in all types of cancer. As a result, gene fusions can occur in the cancer genome. Fusions are major drivers of cancer and are therefore most relevant for treatment decisions. Conventional PCR-based methods will not detect a fusion when the other partner is not known (frequently relevant for neutrophic tyrosine kinase, NTRK fusions). Even whole transcriptome analyses are not sensitive enough, especially when the tumor content is low.

To detect all known and previously described as well as novel gene fusions with a therapeutic option, we developed a next-generation targeted enrichment on RNA-basis. The design currently includes over 150 genes for fusion detection and over 120 exon-exon-specific enrichments with known breakpoints. This method is superior to DNA-based methods and also to whole RNA-based approaches. We strongly recommend completing the genetic tumor diagnostic by RNA enrichment for fusions for the most complete understanding of the tumor’s biology.